Skip to main content

Table 2 Characteristics of screening serum sets

From: Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas

  1st sampling test Validation test
Sampling periods 1998-2005 2005-2008
No. of patients 128 115
Healthy donors, n (%) 56 (43.8) 48 (41.7)
  Age (mean ± SD), range 48.1 ± 18.3, 16-76 51.3 ± 15.2, 16-76
Low-grade glioma, n(%) 40 (31.3) 42 (36.5)
  Age (mean ± SD), range 45.8 ± 14.8, 20-74 44.2 ± 14.1, 22-78
  Pilocytic astrocytoma, n (%) 2 (5.0) 4 (9.5)
  Diffuse astrocytoma, n (%) 18 (45.0) 15 (35.7)
  Oligodendroglioma, n (%) 16 (40.0) 19 (45.2)
  Oligoastrocytoma, n (%) 3 (7.5) 1 (2.4)
  Ependymoma, n (%) 1 (2.5)  
  Ganglioglioma, n (%)   3 (7.1)
High-grade glioma, n (%) 32 (25.0) 25 (21.7)
  Age (mean ± SD), range 49.7 ± 18.3, 8-78 49.8 ± 15.5, 28-78
  Glioblastoma, n (%) 24 (75.0) 17 (68.0)
  Anaplastic astrocytoma, n (%) 5 (15.6) 3 (12.0)
  Anaplastic oligodendroglioma, n (%) 2 (6.3) 2 (8.0)
  Anaplastic oligoastrocytoma, n (%) 1 (3.1) 1 (4.0)
  Anaplastic ependymoma, n (%)   1 (4.0)
  Choroid plexus carcinoma, n (%)   1 (4.0)